1Wyszynska T,Cichocka E,Wieteska-Klimczak A,et al.A sing1e pediatric center experience with 1025 children with hypertension.Acta Paediatr,1992,81:244-246.
2Daniels SB,Loggie JM,McEnery PT,et al.Clinical spectrum of intrinsic renovascular hypertension in children.Pediatrics,1987,80:698-704.
3Deal JE,Snell MF,Barratt TM,et al.Renovascular disease in childhood.J Pediatr,1992,121:378-384.
4Davis JO.The pathogenesis of chronic renovascular hypeertension.Circ Res,1977,40:439-444.
7National high blood pressure education program working group on high blood pressure in children and adolescents.The fourth report on the diagnosis,evaluation,and treatment of high blood pressure in children and adolescents.Pediatrics,2004,114:555-576.
8Kjell T,Eileen B,George H,et al.Renovascular hypertension in children.Lancet,2008,371:1453-1463.
9Teigen CL,Mitchell SE,Venbrux AC,et al.Segmental renal artery embolization for treatment of pediatric renovascular hypertension.J Vasc Interv Radiol,1992,3:111-117.
2Azizi M. Direct renin inhibition: clinical pharmacology. J Mol Med,2008,86:647-654.
3Rella M, Rushworth CA, Guy JL, et al. Structure based pharmacophore design and virtual screening for novel angiotensin converting enzyme-inhibitors. J Chem Inf Model, 2006,46 : 708 -716.
4Huentelman M J, Zubcevic J, KatovichMJ, et al. Cloning and characterization of a secreted form of angiotensin converting enzyme 2. Regu. Pept, 2004, 122:61-67.
5Zhong JC, Huang DY, Yang YM, et al. Up regulation of angiotensin-converting enzyme 2 by alltrans retinoic acid in spontaneously hypertensive rats. Hypertension, 2004, 44 : 907-912.
6Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation Angiotensin - Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin Ⅱ Receptors. Hypertension, 2004,43 : 970-976.
7Breschi M C, Calderone V, Digiacomo M, et al. NO2Sartans: A new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem, 2004,47:5597-5600.
8Alfakih K, Maqbool A, Sivananthan M, et al. Left ventricle mass index and the common functional, X-linked angiotensin type-2 receptorgene polymorphism (21332 GPA) in patients with systemic hypertension. Hypertension, 2004, 43 : 1189- 1194.
9Rosentrem U, Skeld C, Plouffe B, et al. New selective AT2 receptor ligands encompassing a γ'2turn mimetic replacing the amino acid residues 4-5 of angiotensin Ⅱ act as agonists. J Med Chem, 2005, 48:4009-4024.
10Georgsson J, Skeld C, Plouffe B, et al. Angiotensin Ⅱ pseudopeptides containing 1, 3, 5- trisubstituted benzene scaffods with high AT2 receptor affinity. J Med Chem, 2005, 48 : 6620-6630.
6Edwards MS,Corriere MA.Contemporary management of athero-sclerotic renovascular disease.J Vasc Surg,2009,50:1197-1210.
7Rundback JH,Sacks D,Kent KC,et al.Councils on cardiovas-cular radiology,high blood pressure research,kidney in cardio-vascular disease,and clinical cardiology,american heart associa-tion;society of interventional radiology FDA device forum com-mittee.Guidelines for the reporting of renal artery revasculariza-tion in clinical trials.J Vasc Interv Radiol,2003,14:S477-S492.
8Mwipatayi BP,Beningfield SJ,White LE,et al.A review of thecurrent treatment of renal artery stenosis.Eur J Vasc EndovascSurg,2005,29:479-488.
9Robinson WP,Bafford R,Belkin M,et al.Favorable outcomeswith in situ techniques for surgical repair of complex renal arteryaneurysms.J Vasc Surg,2011,53:684-691.
10Radermacher J,Chavan A,Bleck J,et al.Use of Doppler ultra-sonography to predict the outcome of therapy for renal-artery ste-nosis.N Engl J Med,2001,344:410-417.
